AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
CORAL GABLES, Fla. -- Catalyst Pharmaceutical Partners today announced that the U.S. Food and Drug Administration has allowed its Investigational New Drug Application ("IND") to evaluate Catalyst's lead compound, CPP-109, as a potential pharmaceutical therapy for treating cocaine addiction. Allowance of the IND permits Catalyst to initiate a Phase 1 clinical trial, which is designed to assess the safety of the interaction of CPP-109 and cocaine in a clinical setting. Catalyst expects to commence this trial in the first quarter of 2005.
About Catalyst Pharmaceutical Partners
Catalyst Pharmaceutical Partners of Coral Gables, Florida ( …